Abcam, ab312896, Alexa Fluor® 594 Anti-PRAME antibody [EPR20330]

Size: 100µL
Rabbit Recombinant Monoclonal PRAME antibody - conjugated to Alexa Fluor® 594. Suitable for Flow Cyt (Intra) and reacts with Human samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR20330,
Isotype:IgG,
Conjugation:Alexa Fluor® 594,
Excitation/Emission:Ex: 590nm, Em: 617nm,
Carrier free:No,
Reacts with:Human,
Applications:Flow Cyt (Intra)See reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb
patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Alexa Fluor® is a registered trademark of Molecular Probes, Inc, a Thermo Fisher Scientific Company. The Alexa Fluor® dye included in this product is provided under an intellectual property license from Life Technologies Corporation. As this product contains the Alexa Fluor® dye, the purchase of this product conveys to the buyer the non-transferable right to use the purchased product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). As this product contains the Alexa Fluor® dye the sale of this product is expressly conditioned on the buyer not using the product or its components, or any materials made using the product or its components, in any activity to generate revenue, which may include, but is not limited to use of the product or its components: in manufacturing; (ii) to provide a service, information, or data in return for payment (iii) for therapeutic, diagnostic or prophylactic purposes; or (iv) for resale, regardless of whether they are sold for use in research. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, 5781 Van Allen Way, Carlsbad, CA 92008 USA or outlicensing@thermofisher.com.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.4 Preservative: 0.02% Sodium azide Constituents: PBS, 30% Glycerol (glycerin, glycerine), 1% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle|Store in the dark

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
PRAME also known as Preferentially Expressed Antigen in Melanoma is a protein typically weighing around 50 kDa. It is found mostly in testis tissue but also appears in several types of tumors including melanoma and some leukemias. PRAME does not show significant expression in most normal tissues making it a potential target for cancer therapies. Immunohistochemistry (IHC) techniques such as PRAME IHC and PRAME staining often use monoclonal antibodies like mAb EPR20330 to detect PRAME protein presence in various samples.
Biological function summary
PRAME acts as a repressor of retinoic acid signaling a process important for cell differentiation and growth. It does not directly form part of a complex but interacts with components involved in retinoic acid pathways. By binding to retinoic acid receptor complexes PRAME prevents activation of genes involved in cell cycle arrest and apoptosis contributing to unchecked cellular proliferation seen in certain cancers.
Pathways
PRAME participates in the retinoic acid and various oncogenic signaling processes. It influences the retinoic acid pathway by interfering with the retinoic acid receptor (RAR) signaling. This interference with key proteins like RAR disrupts the normal regulatory processes that typically inhibit cancer progression. PRAME's modulation of these pathways highlights its role in promoting tumor growth and survival.
PRAME has significant relevance to cancer particularly melanoma. It is often used as a biomarker for melanoma identification due to its overexpression in such tumors. Additionally PRAME's connection to acute myeloid leukemia (AML) emerges from its ability to act similarly in diverse malignant cells. In these diseases the overexpression of PRAME interferes with normal differentiation processes and allows for sustained proliferation of malignant cells suggesting its potential role as a therapeutic target or diagnostic marker in oncology.